CPhI and P-MEC China closes as the Chinese domestic market continues to expand

International companies are looking to gain a foothold in this lucrative and expanding pharma economy

CPhI and P-MEC China, hosted by UBM EMEA and CCCMHPIE, and co-organised by UBM Sinoexpo, held its most successful event yet at the Shanghai New International Expo Centre(SNIEC) from 24–26 June 2015.

 

This year marked the 15th anniversary of CPhI China, and a decade in partnership with P-MEC. Over the past 10+ years, this event has successfully grown in lieu with the rapidly expanding Chinese market, acting as a central hub for networking and knowledge sharing opportunities – CPhI and the pharma industry in China are inseparable drivers of each other’s development.

   

As discussed in the shortly-to-be-released CPhI Insights Report on the Chinese market, unlike pharma manufacturing in the West, China’s growth is not solely dependent on increasing sales of finished formulations in highly regulated markets – the economic and cost advantages from large-scale API batches are simply too strong to be resisted.

CPhI holds a unique advantage by being the perfect one stop of all our needs

 

The increased interest in this market was reflected at the event, which delivered record numbers in both event scale and attendance for 2015. More than 2,600 global companies exhibited across 150,000m2 of floor space and 64,000+ visitors were welcomed to CPhI and P-MEC China and concurrent event Fi Asia China (FiAC).

 

More than 70 onsite conferences and activities were hosted, covering numerous topics ranging from contract services to environmental protection and clean technology. In particular, the 2nd P-MEC Summit and International Summit for Pharmaceutical Packaging & Drug Delivery Systems achieved remarkable results and highlighted the important role that P-MEC and Innopack China play in the industry.

 

The huge portfolio of content, exhibition halls and industry executives signifies why CPhI and P-MEC China is such a crucial event to the pharmaceutical industry.

Jie Wang, Vice President at Zhejiang Huahai Pharmaceutical Co, said: 'The main benefit for us is being able to meet with all the clients and suppliers at the same time. CPhI holds a unique advantage by being the perfect one stop of all our needs.'

 

As China’s domestic market continues to expand, CPhI and P-MEC China will increasingly update its offering and retain its vital stance as a must-attend event for industry executives from all over the world.

'After CPhI Worldwide, China is the longest running CPhI event and the second largest. With consistent, strong growth forecast for the China pharma market over the next decade, CPhI and P-MEC China remains as crucial as ever in providing an international platform for global pharma executives, manufacturers and suppliers to meet. The key to success for most international manufacturers operating in China is partnering with the right local company and acquiring local knowledge – CPhI is integral to this,' said Chris Kilbee, Group director Pharma, UBM EMEA.

 

'The past 15 years have brought concurrent progress to the event and wider industry and UBM EMEA will continue to uphold the trust of the industry as we look forward to the next 15 years with immutable enthusiasm.'

Companies